SLC12A2 and schizophrenia: Both medications have similar indications and mechanisms of action: potential protective molecular modulation of neuronal transmembrane chloride gradients by blocking NKCC1 in the central nervous system (Kharod et al., 2019), which is the mechanism that led to proposed investigations to treat autism (Lemonnier et al., 2012), schizophrenia (Rahmanzadeh et al., 2017), and epilepsy (Eftekhari et al., 2013; Rahmanzadeh et al., 2017).